Дисертації з теми "Clostridium difficile (C. difficile)"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 дисертацій для дослідження на тему "Clostridium difficile (C. difficile)".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Hecker, Kim Ione. "Bleach-It-Away Clostridium difficile." ScholarWorks, 2018. https://scholarworks.waldenu.edu/dissertations/5471.
Повний текст джерелаMaulner, Stéphanie. "Les endolysines de Clostridium difficile : Potentiel thérapeutique pour traiter les infections à C. difficile (ICD)." Mémoire, Université de Sherbrooke, 2010. http://savoirs.usherbrooke.ca/handle/11143/4059.
Повний текст джерелаTaibi, Fatima. "Études des riborégulateurs c-di-GMP chez Clostridium difficile." Mémoire, Université de Sherbrooke, 2016. http://hdl.handle.net/11143/8785.
Повний текст джерелаSundström, Joakim. "Clostridium difficile – ett växande problem : Om sjuksköterskans arbete för att förebygga spridning av C. difficile i slutenvården." Thesis, Mittuniversitetet, Avdelningen för omvårdnad, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:miun:diva-20170.
Повний текст джерелаVan, Tyle Kendall M. "The Molecular Epidemiology of Clostridium difficile: Description of Clostridium difficile Associated Diarrhea (CDAD) Following a Formulary Change From Levofloxacin to Gatifloxacin." The University of Arizona, 2006. http://hdl.handle.net/10150/624511.
Повний текст джерелаBackground: The processes’ underlying a recent rise in the rate of Clostridium difficile associated diarrhea (CDAD) at the Southern Arizona Veterans Administration Health Care System (SAVAHS) is unclear. Past changes to formulary in workhorse oral flouroquinolone from levofloxacin to gatifloxacin are under scrutiny. An infection-control component was also possible. Methods: 142 patients suspected of having CDAD had stool specimens submitted for toxin assay from late July to late Oct of 2004. A retrospective chart review was performed using the Veterans Administration Computerized Patient Record System (CPRS) to examine total antibiotic use in the three months prior to having specimens submitted for laboratory toxin analysis. A subset-analysis was performed on 100 specimens submitted for toxin analysis. Parallel culture was performed and 9 isolates of C. difficile were obtained for molecular analysis and fingerprinting. Results: Of the 142 patients sampled, 20 tested positive for C. difficile toxin with the remaining 122 patients testing negative. Antibiotic usage was categorized by total antibiotic use and gatifloxacin use. 98 patients received at least 1 antibiotic within the preceding 3 months with 44 patients receiving no antibiotic therapy of any kind. Of the 98 patients that received antibiotic therapy, 44 received gatifloxacin, however, all of these patients also received at least one other antibiotic. Of the nine isolates fingerprinted, two distinct genetic clusters were identified.
Wroe, Allison J. "Immune response to Clostridium difficile infection and an investigation of the mechanisms of moxifloxacin resistance in clinical C. difficile isolates." Thesis, University of Edinburgh, 2010. http://hdl.handle.net/1842/4452.
Повний текст джерелаShaw, Claire M. "Inactivation of Clostridium difficile spores in the healthcare environment using hydrogen peroxide vapour." Thesis, Loughborough University, 2013. https://dspace.lboro.ac.uk/2134/12460.
Повний текст джерелаStehmer, Theresa, and Jackie Campbell. "Evaluation of combination therapy for Clostridium difficile infections at an academic hospital." The University of Arizona, 2012. http://hdl.handle.net/10150/623589.
Повний текст джерелаSpecific Aims: The incidence of non-response, recurrence, relapse, and rate of complications of Clostridium difficile infections treated with combination of metronidazole and vancomycin versus vancomycin or metronidazole alone over a one-year period by treatment and strain type (i.e. NAP1/BI/027) were evaluated. The incidence of mortality in patients with moderate to severe Clostridium difficile associated diarrhea prescribed metronidazole, vancomycin, or combination metronidazole plus vancomycin as initial therapy was also determined. Additionally, significant factors associated with the use of combination vancomycin-metronidazole as initial therapy for moderate to severe CDAD were characterized. Methods: T This retrospective medical record review has been approved by the Institutional Review Board. Adult patients with stool specimens tested for detection of Clostridium difficile toxin B by PCR between April 2010 and March 2011 at a tertiary care, academic medical center were evaluated. Patients were included in the study if diagnosed with moderate to severe disease and received either monotherapy with metronidazole, monotherapy with oral vancomycin, or combination therapy with metronidazole and oral vancomycin for at least 80% of the first 10 days of treatment. Patients who are discharged alive within 72 hours of admission or who received therapy for less than 48 hours were excluded. Main Results: All patients (N=411) with laboratory evidence of Clostridium difficile during the study time period were evaluated. A total of 26 subjects who received oral vancomycin monotherapy and 56 subjects who received oral vancomycin along with metronidazole for at least 80% of the first 10 days of treatment were identified. Of the subjects who received oral vancomycin monotherapy during the first ten days of therapy, 5 (19%) were classified has a treatment failure or died within the first 21 days of therapy and 5 (19%) had either a recurrence or reappearance of Clostridium difficile associated diarrhea between 22 and 65 days post start of therapy. Of the subjects who received a combination of oral vancomycin and metronidazole during the first 10 days of therapy, 14 (25%) were classified has a treatment failure or died within the first 21 days of therapy and 22 (39%) had either a recurrence or reappearance of Clostridium difficile associated diarrhea between 22 and 65 days post start of therapy. In the combination therapy group, 5 (9%) were reported to have an ileus, toxic megacolon, or necrotic bowel during the first 10 days of therapy. Conclusions: In this study, the subjects who received a combination of oral vancomycin and metronidazole had higher rates of clinical failure, death, and recurrence than subjects who received monotherapy. Current guideline statements recommend combination therapy only in patients with an ileus with Clostridium difficile-associated diarrhea.
Feliciano, Lisa. "Clostridium difficile Infection (CDI): Use of Preventive Bundle to Decrease CDI Incidences." ScholarWorks, 2018. https://scholarworks.waldenu.edu/dissertations/5188.
Повний текст джерелаSoavelomandroso, Anna P., Françoise Gaudin, Sandra Hoys, Valérie Nicolas, Gayatri Vedantam, Claire Janoir, and Sylvie Bouttier. "Biofilm Structures in a Mono-Associated Mouse Model of Clostridium difficile Infection." FRONTIERS MEDIA SA, 2017. http://hdl.handle.net/10150/626057.
Повний текст джерелаThanki, Anisha M. "Development of a phage-based diagnostic test for the identification of Clostridium difficile." Thesis, Loughborough University, 2016. https://dspace.lboro.ac.uk/2134/20340.
Повний текст джерелаHörnström, Eva. "The effect of low temperature and transportation time on Clostridium difficile viability." Thesis, Uppsala universitet, Institutionen för kvinnors och barns hälsa, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-295127.
Повний текст джерелаLloyd, Aaron, Vinay Pasupuleti, Priyaleela Thota, Chaitanya Pant, David D. K. Rolston, Adrian V. Hernández, Vicente A. Benítes-Zapata, Thomas G. Fraser, Curtis J. Donskey, and Abhishek Deshpande. "Accuracy of loop-mediated isothermal amplification for the diagnosis of Clostridium difficile infection: a systematic review." Elsevier B.V, 2015. http://hdl.handle.net/10757/345286.
Повний текст джерелаRevisión por pares
Taori, Surabhi Kamal. "Clostridium difficile in south-east Scotland : an analysis of severe, recurrent and community-associated disease with a report on the emergence of PCR ribotype 078." Thesis, University of Edinburgh, 2013. http://hdl.handle.net/1842/8054.
Повний текст джерелаOrellana, Robert Charles. "Recurrent Clostridioides difficile infection: epidemiology and bedside scoring system analysis, 2014-2016." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1543505897011863.
Повний текст джерелаPantaleon, Véronique. "Le biofilm de C. difficile : rôle des protéines de surface." Thesis, Paris 11, 2015. http://www.theses.fr/2015PA114812/document.
Повний текст джерелаClostridium difficile is responsible for twenty-five percent of post-antibiotics diarrhea and for most cases of pseudomembranous colitis. It is an anaerobic, sporulating, Gram-positive bacillus. The bacterium is covered by a two-dimensional lattice called S-layer. It is formed by two subunits of high and low molecular weight after the cleavage of the SlpA precursor by the Cwp84 protease. These two proteins are encoded by genes located in the locus cwp and are secreted by the SecA2 secretion system. They are involved in colonic adhesion/colonization by C. difficile. Adhesion is a common step with biofilm formation by bacteria. The Biofilm is a microbial community embedded in and protected by an extracellular matrix produced by the community members. The biofilm is the main bacterial way of life.We have characterized the SecA2 secretory pathway of C. difficile. The SecA2 protein (as encoded by a gene locus cwp) is essential for the survival of C. difficile. It has a dual location: cytoplasm and intracellular membrane. SecA2 of B. anthracis is able to dimerize with SecA1 and SecA2 proteins of C. difficile. Moreover, the complementation of B. anthracis secA2 mutant with secA2 gene of C. difficile is functional.The role of the S-layer, of the Cwp84 protease and of the motility in the biofilm of C. difficile have also been studied. The 630∆erm strain forms a thin and weak biofilm while the 630∆ermcwp84::erm mutant forms a thick and robust biofilm. We have shown that proteolytic activity of Cwp84 was involved in biofilm formation. Furthermore, a decrease in the translation of slpA RNA with an antisense RNA specific permits an increase in the size of the biofilm of the strain 630∆erm strain. Similarly, the expression of the dominant mutated secA2 allele, which at least partially blocks the SecA2 secretory pathway, increases the biofilm size. Our results suggest that the S-layer, the Cwp84 protease and the SecA2 protein are involved in biofilm formation of C. difficile. On the other hand, we have tested a panel of strains in their capacity to form a biofilm. The results show that non-motile strains are unable to form a thick biofilm.Finally, we have studied the ability of C. difficile to grow aerobically in a mixed biofilm with B. cereus. We highlighted a recruitment and proliferation of C. difficile in the film formed at the air/liquid interface with B. cereus. An optimal ratio of spores of both species is required for the development of C. difficile in these conditions. The presence of C. difficile spores in the film suggests that the environment biofilms could be reservoirs of spores of C. difficile, and the source of human and animal contamination
Youssef, D., Beth A. Bailey, Abbassi A. El, R. Copeland, Leslie G. Adebonojo, T. Manning, and Alan N. Peiris. "Healthcare Costs of Staphylococcus Aureus and Clostridium Difficile Infections in Veterans: Role of Vitamin D Deficiency." Digital Commons @ East Tennessee State University, 2010. https://dc.etsu.edu/etsu-works/6311.
Повний текст джерелаChachaty, Elisabeth. "Evaluation de l'impact des antibiotiques sur la flore intestinale des sujets sainsnotamment sur la colonisation par "Clostridium difficile" ou par des entérobactéries résistantes : comparaison de méthodes de typage des souches de "C difficile"." Paris 11, 1993. http://www.theses.fr/1993PA114842.
Повний текст джерелаSmith, Amelia, Kathyrn Matthias, and Hanna Phan. "Evaluating Treatment Options for NAP1 Versus Non-NAP1 Strains of Clostridium Difficile Infection Among Pediatric Patients at an Academic Hospital." The University of Arizona, 2014. http://hdl.handle.net/10150/614169.
Повний текст джерелаSpecific Aims: The incidence of Clostridium difficile (C. Diff) infections in pediatric patients has continually risen, which could be caused by the emergence of a hyper virulent strain, specifically NAP1/B1/027. The objectives of the study were to evaluate the incidence of strain type, compare treatment(s) prescribed, treatment duration, rate of infection recurrence based on strain and severity, rates of re-infection or recurrence, and treatment failures for patients less than 6 months and up to 18 years of age. Methods: A retrospective study of patients admitted to an academic medical center with detection of C. diff toxin was performed. Data analyses included descriptive and inferential statistics to examine demographics, strain type, infection severity, and treatment failure. Main Results: Fourty-five patients with C. Diff toxin detection were included in study analyses and the median age was 6.2 [0.31- 17.9 years]. Oral or intravenous metronidazole was prescribed as initial therapy in 89% of the patients. Strain type was available in 77% of patients, with NAP1/B1/027 detected in 31% of stool samples tested. Within 21 days after initial toxin detection, there was a 13% rate of clinical failure or death, although none directly associated with C. Diff. Within days 22 - 65 after initial toxin detection, there was a 16% rate of recurrence or reinfection. Initial therapy selection, therapy duration, and rate of recurrence or reinfection were not significantly associated with NAP1/B1/027 strain type. Conclusion: Despite variability in severity of infection, the majority of pediatric patients with C. Diff were treated with metronidazole and were infected with a non-B1/NAP1/027 strain.
Bordeleau, Éric. "Régulation du c-di-GMP et rôle de ce messager secondaire dans la formation de pili de type IV chez Clostridium difficile." Thèse, Université de Sherbrooke, 2014. http://hdl.handle.net/11143/5385.
Повний текст джерелаParisien, Albert. "Large-Scale Production in 'Escherichia coli' TG1 and Purification of Llama Single Domain Antibody ToxA5.1 Against 'Clostridium difficile' Toxin A." Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/26242.
Повний текст джерелаCosmetatos, Isabelle Cosmetatos Isabelle. "Fecal isolation of "Clostridium difficile" and its toxins in horses with typhlo-colitis : Oral administration of neomycin and phthalylsulfathiazole in horses : effects on clinical, hematological and hematochemical parameters and influence on the isolation rate of "C. difficile" in feces /." [S.l.] : [s.n.], 1995. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.
Повний текст джерелаThorsell, Mikaela. "Evaluation of C. diff Quik Chek Complete® and comparison with GeneXpert to establish a new diagnostic algorithm." Thesis, Uppsala universitet, Institutionen för kvinnors och barns hälsa, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-390609.
Повний текст джерелаHamdi, Cassandra. "Clostridium difficile : Rapid typing Clostridium difficile using MALDI-TOF MS analysis." Thesis, Högskolan i Skövde, Institutionen för biovetenskap, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-17659.
Повний текст джерелаCaproni, Lisa J. "Antibiotics and Clostridium difficile." Thesis, University of Edinburgh, 2004. http://hdl.handle.net/1842/24132.
Повний текст джерелаBåverud, Viveca. "Clostridium difficile in horses /." Uppsala : Dept. of Veterinary Microbiology, Swedish Univ. of Agricultural Sciences ([Institutionen för veterinärmedicinsk mikrobiologi], Sveriges lantbruksuniv.), 2002. http://epsilon.slu.se/avh/2002/91-576-6378-5.pdf.
Повний текст джерелаCairns, Michelle Dawn. "Evolution of Clostridium difficile." Thesis, University College London (University of London), 2018. http://discovery.ucl.ac.uk/10060221/.
Повний текст джерелаWheeldon, Laura J. "Studies on Clostridium difficile." Thesis, Aston University, 2008. http://publications.aston.ac.uk/15406/.
Повний текст джерелаKarlsson, Sture. "Toxin production in Clostridium difficile /." Stockholm : Karolinska institutet, 2004. http://diss.kib.ki.se/2004/91-77349-812-2/.
Повний текст джерелаPermpoonpattana, Patima. "Clostridium difficile : infection and immunity." Thesis, Royal Holloway, University of London, 2013. http://repository.royalholloway.ac.uk/items/33009ec4-7815-0803-d39b-f968c8d9cdbb/7/.
Повний текст джерелаUnderwood, Sarah. "Sporulation initiation in Clostridium difficile." Thesis, University of Leeds, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.505066.
Повний текст джерелаMartins, Luís Filipe Pires. "Clostridium difficile uma ameaça renovada." Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2008. http://hdl.handle.net/10216/21105.
Повний текст джерелаCésar, Artur Jorge Fernandes. "Clostridium difficile - prevenção e controlo." Master's thesis, Faculdade de Medicina da Universidade do Porto, 2009. http://hdl.handle.net/10216/50362.
Повний текст джерелаCésar, Artur Jorge Fernandes. "Clostridium difficile - prevenção e controlo." Dissertação, Faculdade de Medicina da Universidade do Porto, 2009. http://hdl.handle.net/10216/50362.
Повний текст джерелаMartins, Luís Filipe Pires. "Clostridium difficile uma ameaça renovada." Dissertação, Instituto de Ciências Biomédicas Abel Salazar, 2008. http://hdl.handle.net/10216/21105.
Повний текст джерелаTicchi, Laurence. "Clostridium difficile et ses toxines : prévalence de "Clostridium difficile" et de la toxine A asymptomatique." Paris 5, 1990. http://www.theses.fr/1990PA05P183.
Повний текст джерелаChilton, Caroline Hazel. "Comparative proteomic analysis of Clostridium difficile." Thesis, University of Edinburgh, 2011. http://hdl.handle.net/1842/5960.
Повний текст джерелаKirby, Jonathan M. "The pathogenesis of Clostridium difficile infection." Thesis, University of Bath, 2011. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.545329.
Повний текст джерелаSchack, Senta. "Clostridium-difficile-Infektion nach herzchirurgischem Eingriff." Doctoral thesis, Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-198482.
Повний текст джерелаWilling, Stephanie. "Assembling the surface of Clostridium difficile." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/45396.
Повний текст джерелаRihn, Bertrand. "Cytotoxine et enterotoxine de clostridium difficile." Strasbourg 1, 1991. http://www.theses.fr/1991STR13025.
Повний текст джерелаSmyth, Deborah. "Stress and survival of Clostridium difficile." Thesis, Ulster University, 2017. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.706470.
Повний текст джерелаVajhi, Jafari N. "Defining innate immunity to Clostridium difficile." Thesis, University College London (University of London), 2012. http://discovery.ucl.ac.uk/1347959/.
Повний текст джерелаRansom, Eric M. "Clostridium difficile: shedding light on pathogenesis." Diss., University of Iowa, 2015. https://ir.uiowa.edu/etd/5828.
Повний текст джерелаKrajewski, Christina [Verfasser]. "Korrelation der Typisierung von Clostridium difficile Isolaten und klinischen Daten der Patienten mit Clostridium difficile Infektion / Christina Krajewski." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2018. http://d-nb.info/1168900581/34.
Повний текст джерелаKerzmann, Amy N. "Mechanistic analysis of Clostridium difficile toxin A." [Bloomington, Ind.] : Indiana University, 2009. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3378359.
Повний текст джерелаTitle from home page (viewed on Jul 12, 2010). Source: Dissertation Abstracts International, Volume: 70-10, Section: B, page: 6182. Advisers: Andrew L. Feig; James T. Drummond.
Mullan, Nivette K. "Mucosal cell responses to Clostridium difficile toxins." Thesis, University of Nottingham, 2011. http://eprints.nottingham.ac.uk/13217/.
Повний текст джерелаJohal, Shawinder Singh. "The pathogenesis of Clostridium difficile induced disease." Thesis, University of Nottingham, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.403400.
Повний текст джерелаAlabdali, Yasir. "Characterisation of antibiotic resistance in Clostridium difficile." Thesis, University of Sheffield, 2017. http://etheses.whiterose.ac.uk/18910/.
Повний текст джерелаHe, Miao. "Genomic variation and evolution of Clostridium difficile." Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.609982.
Повний текст джерела